Scarica l'app Stockscreener
7.12
2.01%
0.14
Dopo l'orario di chiusura:
7.12
Precedente Chiudi:
$6.98
Aprire:
$7
Volume 24 ore:
45,956
Relative Volume:
0.42
Capitalizzazione di mercato:
$35.53M
Reddito:
$34.77M
Utile/perdita netta:
$-74.04M
Rapporto P/E:
-0.9013
EPS:
-7.9
Flusso di cassa netto:
$-79.76M
1 W Prestazione:
-7.05%
1M Prestazione:
+3.79%
6M Prestazione:
-43.97%
1 anno Prestazione:
-80.22%
Intervallo 1D:
$6.80
$7.16
Intervallo di 1 settimana:
$6.80
$7.85
Portata 52W:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Nome
Mersana Therapeutics Inc
Settore
Industria
Telefono
617-498-0020
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Confronta MRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
7.12 | 35.03M | 34.77M | -74.04M | -79.76M | -7.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | William Blair | Outperform |
| 2024-11-15 | Ripresa | Citigroup | Buy |
| 2024-03-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-07-27 | Downgrade | Citigroup | Buy → Neutral |
| 2023-07-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Downgrade | Truist | Buy → Hold |
| 2023-07-27 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-06-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Iniziato | Guggenheim | Buy |
| 2023-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Iniziato | Citigroup | Buy |
| 2022-11-21 | Iniziato | Truist | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-04-29 | Iniziato | BTIG Research | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
Mersana Therapeutics Inc. recovery potential after sell offJuly 2025 PreEarnings & Verified Swing Trading Watchlists - Newser
Leading vs lagging indicators on Mersana Therapeutics Inc. performanceJuly 2025 Analyst Calls & Weekly High Momentum Picks - Newser
Analyzing net buyer seller activity in Mersana Therapeutics Inc.July 2025 Technicals & Verified Momentum Stock Alerts - Newser
Is Mersana Therapeutics Inc. stock reversal real or fakeWeekly Profit Report & Long-Term Safe Return Strategies - Newser
What recovery options are there for Mersana Therapeutics Inc.2025 Technical Overview & Verified Trade Idea Suggestions - Newser
Will Mersana Therapeutics Inc. bounce back from current support2025 Technical Overview & Accurate Intraday Trade Tips - Newser
How moving averages guide Mersana Therapeutics Inc. tradingWeekly Stock Report & Risk Controlled Swing Alerts - Newser
Using Python tools to backtest Mersana Therapeutics Inc. strategiesAnalyst Upgrade & Weekly Return Optimization Plans - Newser
Using data tools to time your Mersana Therapeutics Inc. exitQuarterly Trade Review & Reliable Entry Point Alerts - Newser
Has Mersana Therapeutics Inc. formed a bullish divergenceEarnings Growth Summary & Verified Stock Trade Ideas - Newser
Can Mersana Therapeutics Inc. generate free cash flowJuly 2025 Summary & Consistent Return Strategy Ideas - khodrobank.com
Is Mersana Therapeutics Inc. a top pick in the sector2025 Market Sentiment & Fast Entry High Yield Stock Tips - khodrobank.com
Using Bollinger Bands to evaluate Mersana Therapeutics Inc.Market Growth Summary & Free High Accuracy Swing Entry Alerts - Newser
Sector ETF performance correlation with Mersana Therapeutics Inc.Options Play & High Win Rate Trade Tips - Newser
Is Mersana Therapeutics Inc. reversing from oversold territory2025 Market Overview & Safe Entry Momentum Stock Tips - Newser
What does recent volatility data suggest for Mersana Therapeutics Inc.July 2025 Movers & Daily Stock Trend Reports - Newser
What Fibonacci levels say about Mersana Therapeutics Inc. reboundJuly 2025 Closing Moves & High Yield Stock Recommendations - Newser
Can momentum traders help lift Mersana Therapeutics Inc.2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - Newser
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsWeekly Trend Report & Weekly Setup with ROI Potential - Newser
Key resistance and support levels for Mersana Therapeutics Inc.Earnings Risk Report & Technical Confirmation Alerts - Newser
How sentiment analysis helps forecast Mersana Therapeutics Inc.2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
Chart based exit strategy for Mersana Therapeutics Inc.2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Is Mersana Therapeutics Inc. stock forming a cup and handleJuly 2025 Technicals & Reliable Entry Point Alerts - khodrobank.com
Is now a turning point for Mersana Therapeutics Inc.Trade Exit Summary & High Return Trade Opportunity Guides - Newser
Signal strength of Mersana Therapeutics Inc. stock in tech scannersJuly 2025 Summary & Free Safe Entry Trade Signal Reports - Newser
What’s the beta of Mersana Therapeutics Inc. stockJuly 2025 Price Swings & Stepwise Swing Trade Plans - khodrobank.com
Can Mersana Therapeutics Inc. stock double in the next yearJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - khodrobank.com
Can Mersana Therapeutics Inc. reach resistance levels soon2025 Technical Patterns & Real-Time Volume Analysis - khodrobank.com
Is Mersana Therapeutics Inc. subject to activist investor interestAnalyst Downgrade & Weekly Momentum Picks - khodrobank.com
How does Mersana Therapeutics Inc. perform in inflationary periods2025 Key Lessons & Daily Price Action Insights - خودرو بانک
Evaluating Mersana Therapeutics Inc. with trendline analysisPortfolio Growth Summary & High Accuracy Swing Entry Alerts - Newser
Best data tools to analyze Mersana Therapeutics Inc. stockGold Moves & Precise Entry and Exit Recommendations - Newser
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionWeekly Gains Report & Reliable Intraday Trade Plans - Newser
Can Mersana Therapeutics Inc. recover in the next quarterJuly 2025 Institutional & Weekly Breakout Watchlists - Newser
Developing predictive dashboards with Mersana Therapeutics Inc. dataJuly 2025 Spike Watch & High Yield Stock Recommendations - Newser
Mersana Therapeutics Inc. stock volume spike explainedEarnings Growth Report & Real-Time Chart Breakout Alerts - Newser
Mersana Therapeutics' SVP sells shares worth $4,912 - MSN
Will Mersana Therapeutics Inc. outperform the marketBond Market & Weekly Momentum Stock Picks - Newser
Will Mersana Therapeutics Inc. stock go up soon2025 Investor Takeaways & Safe Entry Momentum Tips - Newser
Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mersana Therapeutics Inc Azioni (MRSN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
| Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):